Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 19 Dec 2017 Planned End Date changed from 31 Dec 2017 to 31 Jan 2019.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Dec 2013 Planned end date 31 Dec 2017 added as reported by University Hospital Medical Information Network - Japan.